GvHD Could Yield To MaaT Pharma's Microbiome-Based Ecosystem Therapies
Phase III Studies Planned
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.
